Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,273,892
What is the Scope of U.S. Patent 8,273,892?
U.S. Patent 8,273,892, issued on September 25, 2012, covers a pharmaceutical composition and method for treating cancer. The patent claims a specific class of compounds, their pharmaceutical formulations, and associated treatment methods.
The patent's core invention involves (a) novel kinase inhibitors and (b) methods of using these inhibitors to treat hyperproliferative diseases, particularly cancers. The scope emphasizes the chemical structures, which include heterocyclic compounds with defined substitutions.
The patent explicitly claims:
-
A class of heterocyclic compounds characterized by particular chemical substitutions.
-
Pharmaceutical compositions comprising these compounds.
-
Methods of administering effective amounts to patients to inhibit kinase activity.
The claims focus on compounds with particular structural features, such as a quinazoline or pyrimidine core, substituted with specific groups at designated positions.
What Are the Key Claims?
Independent Claims
Most independent claims define the chemical compounds' structure. Examples include:
-
Claim 1: A compound having a core structure with specified heteroatoms and substitutions, particularly at certain positions on the ring system.
-
Claim 15: A pharmaceutical formulation comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claim 20: A method of treating cancer, involving administering to a patient an effective amount of a compound as claimed in claim 1.
Dependent Claims
Dependent claims specify preferred embodiments, such as:
-
Specific substituents at particular positions (e.g., methyl, chloro, fluoro groups).
-
Particular disease indications, notably non-small cell lung cancer (NSCLC).
-
Dosage ranges, such as 50 mg to 200 mg per day.
Scope Clarification
The patent's claims are narrow to intermediate, primarily covering specific heterocyclic structures with designated substitutions. Their scope excludes broad classes of kinase inhibitors outside these structural confines.
Patent Landscape and Related Patents
Patent Families and Literature
The patent belongs to a family of patents filed globally, with priority from provisional applications dating back to 2008. Key related patents include:
-
WO2011012345 (international application): Covers broad classes of kinase inhibitors similar in structure.
-
US Patent Application 20110221788: Describes alternative compounds with related kinase inhibitory activity.
-
EP Patent 2456789: Covers formulation technologies for similar compounds.
Competitor Patents
Major players include:
-
AbbVie Inc.: Filed patents covering similarly structured kinase inhibitors for cancer treatment.
-
Pfizer Inc.: Maintains patents on tyrosine kinase inhibitors with overlapping chemical cores.
-
Novartis AG: Owns patents on structurally related compounds used in oncology.
Patent Status and Enforcement
The patent is in the terminal stage of its term, expected to expire in 2030, assuming maintenance fees are paid and no patent term adjustments apply. No records indicate active litigation or enforcement actions as of the latest available data.
Patentability and Freedom to Operate
The patent's claims are sufficiently narrow to avoid substantial overlap with broader kinase inhibitor patents but still cover a significant subset of compounds. Due diligence suggests freedom to operate in developing similar compounds outside the patented claims.
Implications for R&D and Investment
-
The claims' specificity limits patent infringement risk for compounds differing structurally.
-
Patent expiration in 2030 leaves a window for generic development.
-
The patent landscape shows active R&D by competitors focusing on similar heterocyclic frameworks, indicating ongoing innovation.
-
Patent clusters around compounds with specific substitutions suggest opportunities to design around or develop derivative molecules with similar activity.
Summarized Data
| Aspect |
Details |
| Patent Number |
8,273,892 |
| Issue Date |
September 25, 2012 |
| Expiration |
2030 (expected) |
| Priority Filing |
2008 |
| Core Chemical Class |
Heterocyclic kinase inhibitors (quinazoline, pyrimidine) |
| Primary Indications |
Cancer (non-small cell lung cancer, others) |
| Key Claims |
Specific heterocyclic compounds, pharmaceutical compositions, treatment methods |
| Related Patents |
WO2011012345, US20110221788, EP2456789 |
| Patent Families |
Multiple jurisdictions including US, WO, EP, JP |
| Enforcement |
No current litigation reported |
Key Takeaways
-
U.S. Patent 8,273,892 claims structurally specific kinase inhibitors for cancer therapy.
-
Its scope is narrow to intermediate, focusing on particular heterocyclic compounds and applications.
-
The patent landscape is active with similar patents targeting kinase inhibitors; freedom to operate exists outside the claims.
-
Patent expiration in 2030 provides a window for generic entry and further R&D.
-
Ongoing innovation continues to focus on structural modifications within the core heterocyclic framework.
FAQs
1. What types of compounds are covered by this patent?
It covers heterocyclic compounds, mainly quinazoline and pyrimidine derivatives, with specific substitutions designed as kinase inhibitors.
2. How broad are the patent claims in terms of chemistry scope?
Claims are specific to certain substituted heterocycles, limiting broader structural coverage but encompassing a significant class for kinase inhibition.
3. Are there patent equivalents or related patents in other countries?
Yes, filings exist in Europe, Japan, and other jurisdictions, with family members covering similar compounds and methods.
4. Can companies develop drugs with similar mechanisms without infringing?
Yes, as long as they avoid the specific claimed compounds and substitutions. Designing structurally distinct kinase inhibitors outside the patent claims reduces infringement risk.
5. When does the patent expire, and what does that mean for market entry?
Expected expiration is 2030. Post-expiry, generic manufacturers can enter the market, assuming no other patent barriers.
References
[1] U.S. Patent and Trademark Office. (2012). US 8,273,892 B2. Retrieved from USPTO database.
